Zimmer Biomet (ZBH): financials, SEC filings and peers

Zimmer Biomet (ZBH) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in Warsaw, Indiana.

It was founded in 1927 and joined the S&P 500 on August 7, 2001.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Orthopedic, Prosthetic & Surgical Appliances & Supplies”.

Zimmer Biomet at a glance

Revenue (12 months): $8.5B
Revenue growth: +8.6%
Operating margin: 14.2%
Net income (12 months): $807M
Free cash flow (12 months): $1.5B
Cash: $410M
Debt: $7.5B
Diluted EPS (12 months): $4.12

Twelve months to June 30, 2026, from the 10-Q filed August 5, 2026.

Latest twelve months

Over the twelve months to June 30, 2026, Zimmer Biomet reported revenue of $8.5 billion, up 8.6% from a year earlier.

Its operating margin was 14.2%, down 1.9 percentage points from a year earlier: for every $100 of sales, about $14 was left as operating profit.

Net income was $807 million (9.5% of revenue), 2.0% lower than a year earlier.

Operating cash flow was $1.7 billion and capital spending $220 million, leaving free cash flow of $1.5 billion (17.9% of revenue).

At the end of the period it held $410 million in cash and $7.5 billion in debt, a net debt position of $7.1 billion.

The diluted share count fell 2.8% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $6.1 billion in fiscal 2020 to $8.2 billion in fiscal 2025, about 6.1% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin widened from 1.4% to 13.3% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.
Zimmer Biomet reported a net loss in 1 of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$6.8B	$6.9B	$7.4B	$7.7B	$8.2B
Revenue growth	11.4%	1.6%	6.5%	3.8%	7.2%
Operating margin	12.6%	10.0%	17.3%	16.7%	13.3%
Net income	$402M	$231M	$1.0B	$904M	$705M
Free cash flow	$1.4B	$1.2B	$1.3B	$1.3B	$1.5B
Diluted EPS	$1.91	$1.10	$4.88	$4.43	$3.55

Fiscal years as reported in Zimmer Biomet’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

8-K filed September 8, 2026 — Executive or director change; Regulation FD disclosure
8-K filed August 5, 2026 — Other event
10-Q filed August 5, 2026 — quarterly report
8-K filed August 5, 2026 — Earnings results
8-K filed June 29, 2026 — Material agreement; Agreement terminated
8-K filed May 27, 2026 — Shareholder vote results
8-K filed May 12, 2026 — Regulation FD disclosure
10-Q filed May 1, 2026 — quarterly report

All Zimmer Biomet filings on SEC EDGAR

Companies like Zimmer Biomet

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about Zimmer Biomet

Is Zimmer Biomet's revenue growing?

Yes. Revenue for the twelve months to June 30, 2026 was $8.5 billion, up 8.6% from a year earlier, according to its SEC filings.

Is Zimmer Biomet profitable?

Yes. It earned $807 million in net income over the twelve months to June 30, 2026, a net margin of 9.5%.

Does Zimmer Biomet have more cash or more debt?

At June 30, 2026 it had $410 million in cash and $7.5 billion in debt, so more debt than cash.

When did Zimmer Biomet last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on August 5, 2026.

Which companies are similar to Zimmer Biomet?

In the S&P 500, Zimmer Biomet is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM) are in the same group.

Understand the numbers

Source: Zimmer Biomet’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.